Replies to post #1953 on Insmed Inc (INSM)

[digforgold196]

I feel that today's PR was an incredibly desperate step by TRCA! Folks, they see their stock price settling under $5.00 even after the European Orphan Status PR and they KNOW that key institutional investors will soon start DUMPING their stock. If (When) this happens, IMHO, the gig is up. There is NO floor when the institutions start pulling out. We could be talking sub dollar in a few months if they lose those investors plus lose (or at least don't win) the lawsuit and report cruddy sales of their cruddy drug. All in all, strictly IMHO, today was the beginning of the end for TRCA with this poor, desperate excuse for a PR. But really, what else could they do right now? They HAVE to re-establish a base of $5.00 a share or the end times will be upon them for sure!

Best to all INSM investors!

[coinstarz]

Normally, a drug company keeps drug price from the public. The detailed revealing of Increlex pricing may have negative impact to TRCA PPS because Investors know that TRCA will not make a good profit from its drug, so why bother? Almost 50-80% of profits (Increlex) go to CBM and DNA, I really don't know how TRCA can make money to support 90 employees. They don't have R&D, no plant, no pipeline, but they do have blood sucker lawyers. I think TRCA's PR is very bad and sad. I am happy iPlex price is high and makes profits.